Researchers studied ebselen in mice and found that it can stop the toxic activity of C. diff without affecting the other, good bacteria in the gut.
“We find that oral dosing of mice infected with C. difficile resulted in nearly complete blockage of the damage to gut tissues that cause the symptoms in humans,” senior author of the study Matthew Bogyo, PhD, told HealthDay.
Further study will be needed to see if the drug does the same thing in humans.
More articles on C. diff:
Recurrent C. diff meets its match in Merck antibody study
C. diff pesticide found ineffective, EPA takes action
Abnormal vitals and blood tests linked to C. diff complications
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
